# Drug-Induced Cholestasis Secondary to Meropenem in an Elderly Patient: Report of A Rare Case

**Authors:** Abhishek Shrestha, Ahmed Suliman, Talat Bazrbachi, Sung-eun E Kim

PMC · DOI: 10.7759/cureus.103145 · Cureus · 2026-02-07

## TL;DR

An elderly patient developed cholestasis after taking meropenem, showing the need for liver monitoring during antibiotic use.

## Contribution

Reports a rare case of meropenem-induced cholestasis in an elderly patient with a probable causal link confirmed by RUCAM.

## Key findings

- The patient showed significant liver enzyme elevation after six days of meropenem treatment.
- Liver function improved after discontinuing meropenem, indicating a cholestatic drug-induced liver injury.
- RUCAM score of 8 confirmed a probable causal relationship between meropenem and liver injury.

## Abstract

Meropenem is a broad-spectrum carbapenem antibiotic commonly used in hospitals to treat moderate-to-severe infections. Although rare, meropenem can cause drug-induced liver disease, including mild transaminase elevation, cholestasis, or hepatic failure. This report presents an 80-year-old woman admitted after a mechanical fall and diagnosed with a catheter-associated urinary tract infection. Intravenous meropenem was initiated following urine culture confirmation of Citrobacter koseri in the context of worsening confusion and elevated inflammatory markers. Six days after starting meropenem, the patient developed generalised weakness and mild pruritus. Liver function tests showed significant abnormalities: alkaline phosphatase (ALP) 1450 U/L and alanine transaminase (ALT) 415 U/L. Liver function improved after meropenem was discontinued. The pattern of injury was consistent with cholestatic drug-induced liver injury (DILI) (R-value = 1), and an updated Roussel Uclaf Causality Assessment Method (RUCAM) score of 8 indicated a probable causal relationship with meropenem.

This case highlights the importance of considering DILI, even with short-term antibiotic use, especially in elderly patients. Routine monitoring of liver function is recommended for those receiving meropenem. Early recognition and prompt withdrawal of the offending agent are essential for clinical improvement and prevention of complications.

## Linked entities

- **Chemicals:** meropenem (PubChem CID 441130), alkaline phosphatase (PubChem CID 18985873)
- **Diseases:** cholestasis (MONDO:0001751), drug-induced liver injury (MONDO:0005359), urinary tract infection (MONDO:0005247)

## Full-text entities

- **Genes:** GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}
- **Diseases:** anorexia (MESH:D000855), venous insufficiency (MESH:D014689), malignancy (MESH:D009369), weakness (MESH:D018908), conjugated hyperbilirubinemia (MESH:C562885), pain (MESH:D010146), inflammatory (MESH:D007249), liver disease (MESH:D008107), gallbladder disease (MESH:D005705), pruritus (MESH:D011537), vomiting (MESH:D014839), fever (MESH:D005334), hepatotoxic medications (MESH:D000069279), jaundice (MESH:D007565), fatigue (MESH:D005221), confusion (MESH:D003221), diarrhoea (MESH:D003967), skin rash (MESH:D005076), cytomegalovirus (MESH:D003586), autoimmune disease (MESH:D001327), ALF (MESH:D017114), urinary tract infection (MESH:D014552), coagulopathy (MESH:D001778), infections (MESH:D007239), biliary dilatation (MESH:D015529), atrial fibrillation (MESH:D001281), Cholestasis (MESH:D002779), gastrointestinal adverse effects (MESH:D005767), encephalopathy (MESH:D001927), hypertension (MESH:D006973), viral hepatitis (MESH:D014777), right (MESH:C535682), organomegaly (MESH:D016878), ascites (MESH:D001201), AIH (MESH:D019693), Sepsis (MESH:D018805), hepatocellular toxicity (MESH:D006528), DILI (MESH:D056486), allergies (MESH:D004342), autoimmune liver (MESH:D017093), tenderness (MESH:D063806), biliary obstruction (MESH:D001658), nausea, vomiting (MESH:D020250), bacterial infections (MESH:D001424), congestive heart failure (MESH:D006333)
- **Chemicals:** ciprofloxacin (MESH:D002939), bilirubin (MESH:D001663), salbutamol (MESH:D000420), clarithromycin (MESH:D017291), Carbapenems (MESH:D015780), famotidine (MESH:D015738), Meropenem (MESH:D000077731), apixaban (MESH:C522181), fluoroquinolones (MESH:D024841), mebeverine (MESH:C005096), dapagliflozin (MESH:C529054), ropinirole (MESH:C046649), colecalciferol (MESH:D002762), nitrofurantoin (MESH:D009582), penicillin (MESH:D010406), perindopril (MESH:D020913), bisoprolol (MESH:D017298), alkaline phosphate (-), gabapentin (MESH:D000077206), alcohol (MESH:D000438), digoxin (MESH:D004077), spironolactone (MESH:D013148)
- **Species:** Citrobacter koseri (species) [taxon 545], Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12969496/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12969496/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12969496/full.md

---
Source: https://tomesphere.com/paper/PMC12969496